← Home / Zentalis Pharmaceuticals, Inc. (ZNTL)
Stock Analysis
Zentalis Pharmaceuticals, Inc. (ZNTL)
ZNTL
ZNTL · Market data
4.87 +4.62%
Track ZNTL in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when ZNTL price is:
52W Range Position
67%
LOWMIDHIGH
Trend
Constructive
Momentum
Neutral
Updated: 2026-08-05 11:30 UTC
WOI Investment Thesis
Constructive
Confirmation improves above 6.61. Holding above 4.37 keeps the current thesis intact.
⚖️
✓
Fundamentals
Weak / Insufficient
✓
Price Structure
Constructive
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
4.37
↗
Break Above
Confirmation improves above resistance.
6.61
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below 4.37
Recent Company Events
SEC VERIFIED
Latest material filings
MAY
27
●
Management / Board
MEDIUM
ZNTL board and management update
Effective May 22, 2026, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc.
8-K Filing • SEC EDGAR
MAY
12
●
Financial Results
HIGH
ZNTL reports financial results
On May 12, 2026, Zentalis Pharmaceuticals, Inc.
8-K Filing • SEC EDGAR
What's Driving ZNTL?
📈 Technical recovery is improving
Momentum is Neutral. Watch 6.61 for confirmation and 4.37 for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
losing 4.37 would weaken the current structure.
Full Analysis Workspace
Technical Signal
Waiting for Confirmation
▲
No confirmed breakout yet. Watch the next level and momentum behavior.
RSI(14)
56.4
◎
How to read this setup
From a roadmap perspective, the setup is boxed by support near 4.37 and resistance around 5.36. Clearing resistance would strengthen the constructive case, while a failure through support would damage the present setup.
Price Chart
ZNTL — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-08-04
Cash
Cash-flow pressure
TTM free cash flow is negative. P/FCF and FCF yield should be read with caution.
Market Cap
$346.2M
Company size
EV
$314.2M
Debt-adjusted value
P/E
-2.8
Not meaningful
P/B
1.9
Low book multiple
EV/EBIT
-2.2
Not meaningful
P/FCF
-2.8
Not meaningful
FCF Yield
-36.28%
Cash return
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
Financial context is mixed
Financial conditions require selective monitoring.
↗
Revenue Growth
Weak
●
Profitability
Insufficient
≈
Cash Flow
Recovering
⚖
Balance Sheet
Strong
💵 Revenue
0.00
↘ Weak
📈 Net Income
-35.35M
≈ Insufficient
🧮 EPS (Basic)
-0.50
≈ Insufficient
Zentalis Pharmaceuticals, Inc.
Related Opportunities